1. Home
  2. QNCX

as of 01-23-2026 3:43pm EST

$3.06
$0.19
-5.71%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

Founded: 2012 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 167.0M IPO Year: 2019
Target Price: $7.67 AVG Volume (30 days): 979.1K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.21 EPS Growth: N/A
52 Week Low/High: $0.72 - $4.55 Next Earning Date: 11-12-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered QNCX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 0.00%
0.00%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Quince Therapeutics Inc. (QNCX)

Sell
QNCX Dec 26, 2025

Avg Cost/Share

$3.47

Shares

50,000

Total Value

$173,500.00

Owned After

39,179

SEC Form 4

Share on Social Networks: